首页> 美国卫生研究院文献>other >WRN Mutation Update: Mutation Spectrum Patient Registries and Translational Prospects
【2h】

WRN Mutation Update: Mutation Spectrum Patient Registries and Translational Prospects

机译:WRN突变更新:突变谱患者登记和转化前景

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Werner syndrome (WS) is a rare autosomal recessive disorder characterized by a constellation of adult onset phenotypes consistent with an acceleration of intrinsic biological aging. It is caused by pathogenic variants in the WRN gene, which encodes a multifunctional nuclear protein with exonuclease and helicase activities. WRN protein is thought to be involved in optimization of various aspects of DNA metabolism, including DNA repair, recombination, replication, and transcription. In this update, we summarize a total of 83 different WRN mutations, including eight previously unpublished mutations identified by the International Registry of Werner Syndrome (Seattle, WA) and the Japanese Werner Consortium (Chiba, Japan), as well as 75 mutations already reported in the literature. The Seattle International Registry recruits patients from all over the world to investigate genetic causes of a wide variety of progeroid syndromes in order to contribute to the knowledge of basic mechanisms of human aging. Given the unusually high prevalence of WS patients and heterozygous carriers in Japan, the major goal of the Japanese Consortium is to develop effective therapies and to establish management guidelines for WS patients in Japan and elsewhere. This review will also discuss potential translational approaches to this disorder, including those currently under investigation.
机译:Werner综合征(WS)是一种罕见的常染色体隐性遗传疾病,其特征是成年发病表型的星座与内在生物学衰老的加速一致。它是由WRN基因中的致病变异引起的,该变异编码具有核酸外切酶和解旋酶活性的多功能核蛋白。 WRN蛋白被认为与DNA代谢各个方面的优化有关,包括DNA修复,重组,复制和转录。在此更新中,我们总结了总共83种不同的WRN突变,包括由Werner Syndrome国际注册中心(华盛顿州西雅图)和日本Werner财团(日本千叶)确定的8种先前未公开的突变,以及已经报道的75种突变在文学中。西雅图国际注册中心招募了来自世界各地的患者,以研究各种早衰综合征的遗传原因,从而有助于人们了解人类衰老的基本机制。鉴于WS患者和杂合子携带者在日本的患病率异常高,日本财团的主要目标是开发有效的疗法并为日本和其他地区的WS患者建立管理指南。这篇综述还将讨论针对这种疾病的潜在翻译方法,包括目前正在研究的方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号